Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world.

[1]  R. Pratley,et al.  GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials , 2020, Frontiers in Endocrinology.

[2]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[3]  American Diabetes Association.  1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[4]  S. Hadjadj,et al.  Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. , 2019, Diabetes & metabolism.

[5]  M. Gratacós,et al.  Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia , 2019, Journal of clinical medicine.

[6]  D. Cuthbertson,et al.  Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities , 2019, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[7]  T. Vilsbøll,et al.  [Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes]. , 2019, Ugeskrift for læger.

[8]  C. Wysham,et al.  Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting , 2018, Current medical research and opinion.

[9]  K. Khunti,et al.  What have we learnt from “real world” data, observational studies and meta‐analyses , 2018, Diabetes, obesity & metabolism.

[10]  G. Sesti,et al.  Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials , 2017, Acta Diabetologica.

[11]  W. Polonsky,et al.  Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[12]  W. Polonsky,et al.  Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control , 2017, Diabetes Care.

[13]  W. Polonsky,et al.  Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence , 2017, Obesity science & practice.

[14]  K. Khunti,et al.  Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis , 2017, Diabetes, obesity & metabolism.

[15]  D. Witte,et al.  Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom , 2017, Diabetes Therapy.

[16]  S. Grandy,et al.  Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany , 2017, Journal of diabetes science and technology.

[17]  C. McAdam-Marx,et al.  Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes. , 2017, Journal of managed care & specialty pharmacy.

[18]  R. Napoli,et al.  Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta‐analysis from the GetGoal programme , 2017, Diabetes, obesity & metabolism.

[19]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[20]  C. McAdam-Marx,et al.  Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis. , 2016, Clinical therapeutics.

[21]  A. Shaunik,et al.  A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus , 2016, Diabetes Therapy.

[22]  I. C. Team.  Type 2 Diabetes in Adults: Management , 2015 .

[23]  G. Charpentier,et al.  Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study , 2015, Advances in Therapy.

[24]  Diana M. Isaacs,et al.  A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond , 2015, Drugs in context.

[25]  V. Preumont,et al.  ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. , 2015, Diabetes & metabolic syndrome.

[26]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[27]  K. Khunti,et al.  The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis , 2015, PloS one.

[28]  F. Giorgino,et al.  Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) , 2015, Diabetes Care.

[29]  J. Kesavadev,et al.  Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. , 2015, Diabetes & metabolic syndrome.

[30]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[31]  M. Bounthavong,et al.  Association Between Statin Adherence and Cholesterol Level Reduction from Baseline in a Veteran Population , 2013, Pharmacotherapy.

[32]  C. Östenson,et al.  Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE , 2013, Diabetes Therapy.

[33]  D. Jonker,et al.  Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment , 2012, Journal of clinical pharmacology.

[34]  B. Bolibar,et al.  [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. , 2012, Medicina clinica.

[35]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[36]  Catherine H. Yu,et al.  Initiating insulin in patients with type 2 diabetes , 2012, Canadian Medical Association Journal.

[37]  D. Mauricio,et al.  Control of Glycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Primary Care in Catalonia (Spain) , 2012, Diabetes Care.

[38]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[39]  J. Northrup,et al.  Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial , 2010, The Lancet.

[40]  V. Preumont,et al.  One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. , 2010, Diabetes & metabolism.

[41]  Bradley C Martin,et al.  Good and poor adherence: optimal cut-point for adherence measures using administrative claims data , 2009, Current medical research and opinion.